Kornimate/medical-research-clean huggingface dataset:
flo for discogenic pain

Conditions: Discogenic Back Pain

Summary: discogenic pain is pain originating from a damaged vertebral disc and be caused by inflammation, dehydration of the nucleus pulposus, decreased disc height, annular tears and impaired mechanical function of the disc.non-operative treatment may include traction, steroid therapy, methylene blue injection and ablative therapy. however, there are few high quality studies evaluating these treatments for reducing discogenic low back pain and most clinical trials failed to detect significant differences between treatments and placebo therapies. hence, there remains an unmet clinical need.


Eligibility criteria:
inclusion criteria: * subject (male or female) is at least 18 to 70 years of age * diagnosed with single level discogenic back pain confirmed by mri and positive discography per spine interventional society guidelines * diagnosis of disc degeneration with pfirrmann score of 1-3 * subject has failed at least six months of conservative care * subject is symptomatic with axial lower back pain greater than lower limb pain at the intensity of \>6/10 concordant or partially concordant * the subject is able to comply with all post-operative standard of care and follow instructions. exclusion criteria: * subjects has significant disc protrusion, severe lumbar spinal stenosis, spine tumor, severe disc degeneration, or sacroiliac (si) joint syndrome * subject had previous surgery at the disc level * patient has previously received injection of flo within 3 months of screening * the subject is unable to comply with follow-up or not appropriate for inclusion based on investigator decision
22 gauge needle for eus guided tissue acquisition of samples for histologic examination

Conditions: Abdominal Neoplasms

Summary: to determine the yield of tissue biopsy specimen and the diagnostic accuracy of tissue acquisition using a newly developed 22 gauge needle in patients with solid lesions throughout the gi tract.

the use of 22 gauge needle to gather tissue samples under eus guidance has not been associated with an increased risk, and no major complications have been described so far both for the 22 gauge procore needle and for standard 22 gauge.20, 21 potential benefits of this new needle are the possibility of increasing the chance of retrieving tissue specimens for histological examination, with the possibility of increasing the diagnostic accuracy of the procedure saving the need and the cost deriving from on-site cytopathology examination. this may reduce the need to repeat eus procedures or other more invasive sampling procedures, including surgery.

Eligibility criteria:
inclusion criteria: * age greater than 18 and less than 80. * presence of a solid lesion within or adjacent of the gastrointestinal tract. in the presence of a cystic component, the solid part of the lesion should be more 75% of the total. * absence of an uncorrectable coagulopathy as defined by abnormal prothrombin time (pt) or partial thromboplastin time (ptt) that does not normalize after administration of fresh frozen plasma. * informed consent is obtained exclusion criteria: * previous biopsy of the lesion with diagnosis of malignancy * presence of an uncorrectable coagulopathy as defined by abnormal prothrombin time (pt) or partial thromboplastin time (ptt) that does not normalize after administration of fresh frozen plasma. * they are unable to understand and/or read the consent form.

Keywords: eus-guided biopsy
intralesional injection of acyclovir versus candida antigen in treatment of plantar warts

Conditions: Acyclovir and Candida Antigen in Treatment of Plantar Wart

Summary: this study aims to evaluate the efficacy of intralesional injection of acyclovir versus candida antigen in plantar wart patients will be randomly divided into 2 groups,at least 20 patients will be enrolled in each group. group 1: will be treated with intralesional injection of acyclovir 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. the base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) every 2 weeks until the resolution of warts or for a maximum of 5 sessions group 2: will be treated by intralesional candida antigen injection (candida antigen ) at a dose of 0.2 ml. injected into the largest wart every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions. 3.patient evaluation: assessment of treatment efficacy and side effects will be carried out by clinical examination and comparative photographic evaluation and dermoscopy

patients will be randomly divided into 2 groups, group (1) and group (2). at least 20 patients will be enrolled in each group. group 1: will be treated with intralesional injection of acyclovir (acyclovir 250mg powder for solution for infusion, each vial contains 250mg of acyclovir as the sodium salt, chandra bhagat pharma pvt. ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. during the study, the dosage of the drug and frequency of treatment were uniform in all patients. the base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions group 2: will be treated by intralesional candida antigen injection (candida antigen ) at a dose of 0.2 ml. injected into the largest wart using an insulin syringe (29 gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions. patients will be followed up for 3months after treatment.

Eligibility criteria:
inclusion criteria: * the study will include patients with single or multiple planter wart. age group 18:50 years old exclusion criteria: * : patients with history of renal or liver disease, pregnant and lactating females, patients taking immunosuppressant drugs, patients who received any treatment for wart in the last month before the study.

Keywords: acyclovir ,candida antigen ,plantar wart
perineal reconstruction following elape and simultaneous stoma sublay reinforcement

Conditions: Rectal Cancer

Summary: this is a prospective, multicenter, single arm, observational pilot study to assess the clinical outcomes of strattice reconstructive tissue matrix for perineal reconstruction following elape and simultaneous stoma reinforcement.

about 40 subjects will be enrolled from 4 centers over approx 24 months. subjects will all be undergoing extralevator abdominoperineal excision with concomitant ostomy creation.

Eligibility criteria:
inclusion criteria: * primary cancers undergoing curative surgery (r0) * life expectancy \> 2 yrs * neoadjuvant radiotherapy with or without chemotherapy exclusion criteria: * pelvic extenteration or extended resections * previously irradiated patients (i.e. radiation therapy for a previous cancer) * co-morbidities of: systemic infection, chronic liver failure, chronic renal failure, hiv, hepatitis c, other advanced/metastatic cancer, collagen disorder * sensitivity to porcine derived products or polysorbate

Keywords: elape, perineum, pelvic floor reconstruction
effects of early short-term intravenous iron supplements combined epo in preterm infants

Conditions: Malnutrition

Summary: there are wide variations in iron supplementation practices in nicu.guidelines on pediatric parenteral nutrition suggested the dose of 200μg/kg.d iron by parenteral nutrition.

the study was approved by the ethics committee of xinhua hospital, and all parents gave written informed consent. study design this was a randomized, controlled, double-blind, interventional trial of iron (iron sucrose) supplementation given from age of 1 day until full 2 weeks to preterm infants in nicu, who divided into three groups, control(pn without iron and epo), vifor and vifor and epoe group, according to the recommended dosage of espen . outcome measures general information and indicators including anemia iron storage were measured. and the same time oxidative stress indicators were monitored at age of 1day and 2 weeks. general growth parameters including the blood sugar, liver and renal function index before and after the intervention were tested. hematological evaluation including rbc, hb, mcv, mch, mchc, ret, crp were mesured before and after the intervention. the three groups were all peripheral blood. iron storage evaluation including ferritin, serum iron, tibc on the days were measured before and after the intervention. we used the radio-immunoassay method to test the ferritin (dade behring, germany), the chemical method to the serum iron and the automatic biochemical analyzer (automatic biochemical analyzer, 7600, hitach).

Eligibility criteria:
inclusion criteria: * preterm infants with birth weight less than 2.5kg have parenteral nutrition indication with written informed consent of parents or guardian exclusion criteria: * kidney and liver function abnormal have hemolytic disease have hemorrhagic disease have serious congenital malformation have septicemia have plethora newborn use tpn less than ten days

Keywords: epo intravenous iron iron storage preterm anemia
perfluorocarbon (abl-101) oxygenation for stroke: trial with gold (glasgow oxygen level dependent technology) imaging theranostic

Conditions: Acute Ischaemic Stroke

Summary: this study evaluates the safety and tolerability of 3 dose levels of abl-101 and supplemental oxygen in acute stroke patients.

only a small proportion of patients are currently suitable for treatment with "clot busting" drugs after a stroke. being able to visualise potentially rescuable brain tissue on scanning may allow more people to be treated. currently available methods require extra time to acquire and are not therefore widely used. by carrying significant extra oxygen to the brain, the abl-101 molecule may not only allow the visualisation of salvageable tissue, but also prevent progression of stroke damage in and have an additional direct benefit on tissue survival. studies in animal models of stroke show smaller areas of stroke damage after abl-101. there is therefore a rationale for testing this molecule in stroke patients, both as a diagnostic method, and also as a potential therapeutic agent.

Eligibility criteria:
inclusion criteria: * aged ≥18 years. * males or females not of child-bearing potential defined as being post-menopausal based on cessation of regular menses for a minimum of 12 consecutive months with no alternative cause, permanently sterilised (e.g. hysterectomy, bilateral tubal occlusion, bilateral salpingectomy), or having medically confirmed ovarian failure. * ischaemic stroke \<72h after onset. * previous functional independence (estimated mrs \<3). * capacity to consent. exclusion criteria: * women of child bearing potential. * contraindications to mri scanning (eg cardiac pacemaker, ferromagnetic implants, known hypersensitivity to gadolinium containing contrast media). * known allergy to abl-101 or any of its constituents, (including egg phospholipids). * clinical need for, or contraindication to, supplemental oxygen. * known impaired renal function (egfr \<30ml/min) precluding radiological contrast. * known thrombocytopaenia (platelet count \<150x109) or history of platelet function disorder. * known intercurrent infection. * known severe copd or cardiac failure (eg significantly limiting exercise capacity or requiring hospitalisation within the preceding 12 months). * known significant liver disease (eg liver failure or cirrhosis, chronic infectious or autoimmune hepatitis, or transaminases \>3 times upper limit of normal). * any current medical condition causing impaired immunity (eg hiv infection, hyposplenism) or use of systemic immunosuppressant medication except for inhaled, nasal intra-articular or topical corticosteroids) on an ongoing basis or within the preceding 30 days. * any medical condition potentially limiting survival within the study follow-up period. * participation in another ctimp within preceding 90 days.
the relationship of dash and mediterranean diet score with serum adiponectin levels in patients with spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the aim of this study is to reveal the relationship of dash and mediterranean diet score with anthropometric measurements and serum adiponectin level in individuals with spinal cord injury. this research was planned as a cross-sectional, case-control study. with the data to be obtained from the research, information will be obtained about the hormonal or biochemical basis of metabolic disorders such as atherosclerosis and insulin resistance that may occur in individuals with spinal cord injury in the long term. 20 individuals with spinal cord injury will be included in the study, and the results of the patients will be compared with 20 healthy individuals. in order to determine the food consumption status of the patients, a 1-day food consumption record will be requested. dash diet score and mediterranean diet score will be calculated from dietary records. after 8 hours of fasting, 3 ml of peripheral blood will be taken for the measurement of adiponectin between 08:00 and 09:00 in the morning from the individuals in the study and control groups. adiponectin level will be measured and its correlation with dash diet score and mediterranean diet score will be examined.


Eligibility criteria:
inclusion criteria: * inclusion criteria (study group) * having spent at least 6 months after spinal cord injury * 1st motor neuron injury * being between the ages of 18-65 * giving consent to participate in the study inclusion criteria (control group) * being between the ages of 18-65 * giving consent to participate in the study exclusion criteria: * exclusion criteria (study group) * having an additional disease to the spinal cord injury * having a 2nd motor neuron lesion exclusion criteria (control group) • having any disease

Keywords: adiponectin
comparison of qol for sutureless thyroidectomy

Conditions: Thyroidectomy; Quality of Life

Summary: patients underwent thyroidectomy filled an computer or paper based qol questionnaire before and after operation.

patients who have consent to undergo to total thyroidectomy with sutureless technique (regardless of attending to study or not) for benign thyroid diseases in the institution are asked to participate to this study. patients are informed that participating to this study will not alter their treatment method. patients were operated either with ligasure smalljaw or harmonic focus according to result of label picked from bag. same surgical team performed all operations and they did not know if the patient was participated in study or not. patients willing to participate in this study are being questioned for their quality of life (qol) with a patient-reported outcome (pro) questionnaire before surgery and 4 weeks after surgery. for assessment of quality of life thy-pro-39 questionnaire is being used. responses of patients to qol questionnaire is being recorded to a secure online database. after data completion answers of patients will be exported as anonymous to principal investigator for analysis. effect of two energy based devices (ebd) on qol will be compared.

Eligibility criteria:
inclusion criteria: * sutureless thyroidectomy for benign conditions exclusion criteria: * known neck malignity, * history of neck operation * ligation use during surgery * refusal of patient * non-capable patient * non-euthyroid patient * pregnancy * having rheumatic diseases * having connective tissue diseases
s-cystatin c vs.injection clearance measurements to estimate kidney function in patients with spinal cord injuries

Conditions: Spinal Cord Injuries; Renal Failure

Summary: * in individuals with spinal cord injury (sci) kidney function defined as glomerular filtration rate (gfr) is monitored by injection of e.g.99mdtpa and subsequent blood sampling (dtpa-clearance) * gfr calculated from plasma samples of the endogenous substance s-cystatin c (egfr cystatin c) was compared to dtpa-clearance in 248 individuals with sci. * it is concluded that egfr based on plasma s-cystatin c can replace the more tedious 99mdtpa-clearance procedures in individuals with sci


Eligibility criteria:
inclusion criteria: neurogenic bladder dysfunction due to spinal cord injury exclusion criteria: none

Keywords: spinal cord injury renal failure gfr glomerular filtration rate dtpa clearance cystatin c egfr
visual maturation in premature newborns according to factors influencing its development

Conditions: Delayed Visual Maturation

Summary: the purpose is to describe the level of visual maturation of premature newborns at term equivalent age. the secondary purpose is to determine factors associated to an altered level of visual maturation, through an exploratory approach.


Eligibility criteria:
inclusion criteria: * infants born before 33 weeks of amenorrhea and hospitalized at chru nancy exclusion criteria: * parental opposition * ocular malformation * face malformation * cranial stenosis * chromosomal abnormality

Keywords: infant premature diseases
ucsf panc cyst registry

Conditions: Pancreatic Cyst; Pancreatic Neoplasms; Pancreatic Cancer; Pancreatic Diseases; Pancreatic Intraductal Papillary Mucinous Neoplasm; Intraductal Papillary Mucinous Neoplasm; Pancreatic Ductal Adenocarcinoma; Mucinous Cyst

Summary: pancreatic cysts are found incidentally on 15-50% of ct and mris for all indications and their prevalence is increasing. many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. this presents a clinical challenge to prevent unnecessary resection of indolent disease, with associated risks of infections, bleeding, diabetes, and costly disability. unfortunately, there is little information on the epidemiology and natural history of pancreatic cysts to help guide management.

this study develops a large, prospectively managed, electronic, patient-directed pancreatic cyst registry based at ucsf. the ucsf pancreatic cystic lesions registry (panc cyst) will facilitate work to improve clinical care and understanding of pancreatic cysts by prospective follow-up of patients with cystic lesions, especially the diagnostically challenging small cysts, to identify factors related to cyst formation and progression to malignancy. longitudinal data capture that includes clinical outcomes will also enable us to more precisely define anatomic, radiographic and biomarker information that can be used to differentiate populations of patients for whom surgery is indicated, surveillance is warranted, or no further evaluation is necessary.

Eligibility criteria:
inclusion criteria: * the inclusion criteria for this study are intentionally broad. eligible patients for prospective enrollment will include * adults ≥ 30 years of age * have a radiographic or endoscopic diagnosis of at least one pancreatic cysts regardless of treatment status, * no history of pancreatic cancer, * can speak and read english, * have access to a computer or mobile device (\~95% of u.s. population); and * are able to complete an electronic informed consent. exclusion criteria: * patients who don't speak english, * don't have access to a computer or mobile device; or * patients who have a cancer diagnosis.

Keywords: pancreatic cyst pancreatic cystic lesion pancreatic cancer intraductal papillary mucinous neoplasm serous cystadenoma mucinous cystic neoplasm cancer epidemiology early detection research
study of inactivated, split-virion influenza vaccine administered by intradermal route versus vaxigrip® in adults

Conditions: Influenza; Orthomyxoviridae Infection; Myxovirus Infection

Summary: this is a follow-up of a previous dose-ranging study aimed at investigating 2 doses of the trivalent inactivated split virion influenza vaccine when administered by intradermal route with that of the current pharmaceutical presentation administered by intramuscular route. primary objective: to assess the immunogenicity of two pharmaceutical presentations of the trivalent inactivated split virion influenza vaccine 21 days after a single injection in subjects aged 18 to 57 years. secondary objective: to evaluate the safety profile during the 21-day period following each vaccination in each study group

this is an open (for the administration route) and double-blind (only for the two dosages administered at year 0 by using the investigational administration route) randomized trial conducted in subjects aged 18 to 60 years. the subjects will receive three vaccine injections at 1-year interval.

Eligibility criteria:
inclusion criteria : * subject aged between 18 and 57 years (i.e., less than 60 at the last vaccination) * for woman of child-bearing potential, negative urine pregnancy test at v#01 * use of effective contraception prior to and during the trial * subject available during the trial period * subject able to read and understand the informed consent form * informed consent form signed and dated by the subject prior to any protocol-required intervention (and visit 05 and visit 07, respectively). exclusion criteria : * self-reported allergy to egg proteins, chick proteins, or any of the constituents of the vaccine, in particular, neomycin, formaldehyde, and octoxinol 9 * acute febrile disease within the 72 hours preceding v#01, or axillary temperature \>37.5°c the day of inclusion, prior to vaccination (\>37.0°c czech republic) * subject with an aggravation of existing chronic illness (heart disease, respiratory disease, etc.) * vaccination against influenza within the 6 months preceding v#01 * any vaccination within the 28 days preceding v#01 or scheduled between v#01 and v#02 * breast-feeding * immunosuppressive therapy including long term systemic corticotherapy (20 mg/day of prednisolone or equivalent for \>2 weeks) or cancer therapy within the month preceding v#01 or ongoing * immunoglobulin injection within the 3 months preceding v#01 * subject taking part or planned to take part in another clinical trial (3 months before and through the trial duration) * subject having received extracted pituitary hormones * subjects who participated in the gid01 study (lithuanian centers)

Keywords: influenza orthomyxoviridae infection inactivated, split-virion influenza vaccine intradermal injection adults.
launch ii: a pilot randomized control trial of a clinic and clinic plus home intervention for preschool obesity

Conditions: Obesity

Summary: the objective of this project is to pilot test a behavioral intervention that includes a home visit component compared to a clinic only and standard of care for the treatment of obesity in preschool age children. the results of this study will inform the design of a larger randomized control trial. h1: the clinic + home intervention will result in a significantly greater decrease in bmiz compared to the in clinic only intervention or pediatric standard of care at 6 months post-treatment.


Eligibility criteria:
inclusion criteria: * 2 years 0 months to 5 years 11 months of age * at or above the 95th percentile bmi for age and sex * have at least one parent with a bmi at or greater than 25 * medical clearance from pediatrician exclusion criteria: * non-english speaking * living greater than 50 miles from medical center * a disability or illness that would preclude engagement in moderate activity * medical condition/medication associated with weight * enrolled in another weight management program

Keywords: behavioral treatment preschool aged children obesity